Biogen (BIIB) has risen sharply, recording gains of 6.29% in the past 4 weeks. However, the stock has corrected -2.73% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 6.51% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 1.56% and the fifty day Moving Average is 11.2%. Biogen Inc. is up 8.97% in the last three month period. Year-to-Date the stock performance stands at 0.59%.
Biogen (BIIB) : The highest short term price target forecast on Biogen (BIIB) is $414 and the lowest target price is $283. A total of 14 equity analysts are currently covering the company. The average price of all the analysts is $351.14 with a standard deviation of $40.66.
Biogen (NASDAQ:BIIB): stock turned positive on Friday. Though the stock opened at $307.21, the bulls momentum made the stock top out at $310.74 level for the day. The stock recorded a low of $304.56 and closed the trading day at $308.17, in the green by 0.43%. The total traded volume for the day was 1,124,177. The stock had closed at $306.85 in the previous days trading.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.